Polish leukemia drug has been administered to the first patient

SEL24 compound, developed in Poland, is a very promising anticancer drug for oral use in refractory acute myeloid leukemia.

„SEL24 compound is a dual inhibitor of PIM and FLT3 kinases, which play a key role in the process of cancer formation, which is acute myeloid leukemia. SEL24 is the world’s first potential drug using such a mechanism of action” – stated Selvita in a press release .

– The administration of SEL24 to patients sets a precedent in the history of our biotechnology industry – We are probably the first Polish company to start clinical trials in the United States of a drug thatóry was developed from scratch in a national research laboratory. We hope that póhe success of róAlso in the medical dimension,” said Dr. Krzysztof Brzózka, Chief Scientific Officer and Executive Vice President of Selvita S.A.

Selvita’s clinical phase I/II trials are being conducted in the United States. Last summer, it received approval from the U.S. Food and Drug Administrationów (FDA). SEL24 has been approved for clinical trials with patientsóin suffering from acute myeloid leukemia.

The SEL24 compound is to be aimed at patientów with relapsed or refractory forms of acute myeloid leukemia. In the treatment of this cancer, the mainóThe ultimate goal is to achieve remission or significantly extend the life of the patient.

But SEL24 is manifesting róAlso the potential in treating other cancersóin hematological diseases such as non-Hodgkin’s lymphoma, malignant granuloma and multiple myeloma. In addition, it also increases the effectiveness of treatment in animal models in wsp therapyóhe company’s current drugs.

Selvita is a Polish biotech company and one of the largest of its kind in Europe in the field of drug research and developmentów used in the treatment of chorób cancer, chorób central nervous system and diseaseób autoimmune.